Scarica l'app Stockscreener
45.16
3.65%
-1.6707
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BHVN Giù?
Forum
Previsione
Precedente Chiudi:
$46.83
Aprire:
$46.82
Volume 24 ore:
68,339
Relative Volume:
0.07
Capitalizzazione di mercato:
$4.69B
Reddito:
-
Utile/perdita netta:
$-746.61M
Rapporto P/E:
-6.0454
EPS:
-7.47
Flusso di cassa netto:
$-485.24M
1 W Prestazione:
-7.27%
1M Prestazione:
-12.12%
6M Prestazione:
+16.53%
1 anno Prestazione:
+52.79%
Intervallo 1D:
$45.00
$47.66
Intervallo di 1 settimana:
$43.18
$49.56
Portata 52W:
$26.80
$62.21
Biohaven Ltd Stock (BHVN) Company Profile
Nome
Biohaven Ltd
Settore
Industria
Telefono
203-404-0410
Indirizzo
215 CHURCH STREET, NEW HAVEN, CT
Confronta BHVN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| BHVN | 45.19 | 4.69B | 0 | -746.61M | -485.24M | -7.47 |
| VRTX | 446.39 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 740.49 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.15 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.56 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.47 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Biohaven Ltd Stock (BHVN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-09-16 | Iniziato | Jefferies | Buy |
| 2024-09-04 | Iniziato | Bernstein | Outperform |
| 2024-07-24 | Iniziato | Morgan Stanley | Overweight |
| 2024-02-16 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-02-06 | Iniziato | UBS | Buy |
| 2023-12-22 | Iniziato | H.C. Wainwright | Buy |
| 2023-12-08 | Iniziato | Robert W. Baird | Outperform |
| 2023-01-24 | Iniziato | SVB Securities | Outperform |
| 2023-01-04 | Iniziato | JP Morgan | Overweight |
| 2022-12-02 | Iniziato | BTIG Research | Buy |
| 2022-10-26 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2022-10-12 | Iniziato | Piper Sandler | Overweight |
| 2022-08-19 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-08-08 | Downgrade | Wedbush | Outperform → Neutral |
| 2022-05-11 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2021-10-19 | Ripresa | Morgan Stanley | Equal-Weight |
| 2021-08-10 | Downgrade | UBS | Buy → Neutral |
| 2021-08-03 | Reiterato | Canaccord Genuity | Buy |
| 2021-03-11 | Iniziato | UBS | Buy |
| 2020-12-15 | Iniziato | H.C. Wainwright | Buy |
| 2020-04-17 | Iniziato | Cowen | Outperform |
| 2020-02-10 | Downgrade | Oppenheimer | Outperform → Perform |
| 2020-02-06 | Iniziato | Mizuho | Buy |
| 2019-11-22 | Iniziato | Wedbush | Outperform |
| 2019-06-25 | Reiterato | Canaccord Genuity | Buy |
| 2019-05-06 | Iniziato | Goldman | Buy |
| 2019-04-09 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2019-03-04 | Reiterato | Needham | Buy |
| 2018-07-03 | Reiterato | Needham | Buy |
| 2018-07-02 | Reiterato | Needham | Buy |
| 2018-04-05 | Downgrade | Barclays | Overweight → Equal Weight |
| 2018-02-22 | Reiterato | Canaccord Genuity | Buy |
| 2017-12-15 | Iniziato | Canaccord Genuity | Buy |
| 2017-10-03 | Reiterato | Needham | Buy |
Mostra tutto
Biohaven Ltd Borsa (BHVN) Ultime notizie
Multiple System Atrophy Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | Ionis Pharma, Biohaven Pharma, Lundbeck A/S, Alterity Therapeutics, Theravance Biopharma - The Globe and Mail
Psoriasis Market is expected to rise at a significant CAGR, DelveInsight | Hangzhou Highlightll Pharmaceutical Co., Ltd, Biohaven Pharmaceuticals, Inc., SFA Therapeutics, Bristol-Myers Squibb - Barchart
Biohaven Ltd. (NYSE:BHVN) Shares Sold by First Turn Management LLC - MarketBeat
Victory Capital Management Inc. Has $18.17 Million Holdings in Biohaven Ltd. (NYSE:BHVN) - MarketBeat
Biohaven (NYSE:BHVN) Stock Price Down 8%Should You Sell? - MarketBeat
Janus Henderson Group PLC's Strategic Acquisition of Biohaven Lt - GuruFocus.com
Biohaven's (BHVN) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Biohaven Reports Third Quarter 2024 Financial Results and Recent Business Developments - The Malaysian Reserve
Biohaven shares rise as TD Cowen lifts price target to $75 - Investing.com Australia
Royal Bank of Canada Issues Pessimistic Forecast for Biohaven (NYSE:BHVN) Stock Price - MarketBeat
12,400 Shares in Biohaven Ltd. (NYSE:BHVN) Acquired by SpiderRock Advisors LLC - MarketBeat
Trend Tracker for (BHVN) - Stock Traders Daily
Brokerages Set Biohaven Ltd. (NYSE:BHVN) Price Target at $61.92 - MarketBeat
Biohaven Stock Soars on Drug Trial Results: Time to Jump In? - MSN
Vanguard Group Inc's Strategic Acquisition in Biohaven Ltd - GuruFocus.com
(BHVN) Technical Data - Stock Traders Daily
Biohaven's (BHVN) "Overweight" Rating Reiterated at Cantor Fitzgerald - MarketBeat
Cadent Capital Advisors LLC Invests $1.77 Million in Biohaven Ltd. (NYSE:BHVN) - MarketBeat
(BHVN) Trading Advice - Stock Traders Daily
Scholar Rock stock could benefit from Biohaven's Ph3 results, Truist raises potential rally outlook - Investing.com India
BofA sustains Buy rating on Biohaven shares, sees SMA trial upside By Investing.com - Investing.com South Africa
BofA sustains Buy rating on Biohaven shares, sees SMA trial upside - Investing.com UK
Analysts Set Biohaven Ltd. (NYSE:BHVN) Target Price at $61.92 - MarketBeat
Biohaven: A Complicated Tale (NYSE:BHVN) - Seeking Alpha
Biohaven Ltd. (NYSE:BHVN) Shares Acquired by AQR Capital Management LLC - MarketBeat
(BHVN) Investment Analysis - Stock Traders Daily
17,064 Shares in Biohaven Ltd. (NYSE:BHVN) Acquired by Squarepoint Ops LLC - MarketBeat
Biohaven retains Outperform stock rating on clinical results By Investing.com - Investing.com South Africa
Biohaven holds steady with $60 target on SMA trial optimism - Investing.com India
Biohaven holds steady with $60 target on SMA trial optimism By Investing.com - Investing.com Australia
Biohaven maintains Buy rating with $59 target amid SMA trial optimism By Investing.com - Investing.com South Africa
Biohaven (NYSE:BHVN) Stock Price Up 4.9%Here's What Happened - MarketBeat
Vladimir Coric Buys Handful Of Shares In Biohaven - Simply Wall St
Cantor Fitzgerald Reiterates "Overweight" Rating for Biohaven (NYSE:BHVN) - MarketBeat
Biohaven Stock Spikes After Drug Candidate To Treat Rare Neurodegenerative Disease Shows Promise - MSN
Analysts’ Recent Ratings Changes for Biohaven (BHVN) - Defense World
Biohaven (NYSE:BHVN) Price Target Raised to $68.00 at JPMorgan Chase & Co. - MarketBeat
Biohaven (NYSE:BHVN) Shares Gap Up After Insider Buying Activity - MarketBeat
John W. Childs Purchases 21,052 Shares of Biohaven Ltd. (NYSE:BHVN) Stock - Defense World
Bullish Biohaven Insiders Loaded Up On US$41.7m Of Stock - Yahoo Finance
Biohaven director Childs buys shares worth nearly $1 million By Investing.com - Investing.com South Africa
Biohaven CEO Vlad Coric acquires $999,970 in company stock By Investing.com - Investing.com Australia
Biohaven director Childs buys shares worth nearly $1 million - Investing.com
Biohaven CEO Vlad Coric acquires $999,970 in company stock - Investing.com India
Marshall Wace LLP Sells 677,724 Shares of Biohaven Ltd. (NYSE:BHVN) - MarketBeat
Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares - Lelezard.com
Biohaven Ltd. (NYSE:BHVN) Shares Sold by Point72 Asset Management L.P. - MarketBeat
Biohaven sets public offering price at $47.50 per share By Investing.com - Investing.com Australia
Biohaven shares could see growth as MDD and bipolar studies advance, per TD Cowen - Investing.com India
Biohaven (NYSE:BHVN) Sees Strong Trading Volume - MarketBeat
Biohaven sets public offering price at $47.50 per share - Investing.com
Biohaven Ltd Azioni (BHVN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.42%
0.16%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):